Experience China’s Vaccine Innovation: CanSinoBIO Unveils Breakthroughs at the 2025 World Government Summit in Dubai

DUBAI, UAE – February 17, 2025 – CanSino Biologics Inc. (CanSinoBIO), a top Chinese vaccine developer, attended the 2025 World Government Summit held in Dubai from February 11-13. Dr. Yu Xuefeng, the Chairman and CEO, and Ms. Wang Jing, the Chief Commercial Officer, presented the company’s innovative technologies and health strategies at this global event.

The World Government Summit (WGS 2025) gathers leaders, heads of state, and tech experts from 140 countries. The aim is to work together on global challenges, assess progress, and create better futures through effective governance and sustainability.

CanSinoBIO’s presence at the summit marks a key step in its global outreach and demonstrates its dedication to public health. By connecting with international leaders, CanSinoBIO hopes to boost its role in the biopharmaceutical sector, encouraging innovation and meaningful partnerships for global impact.

Global Health Solutions

CanSinoBIO is committed to being a worldwide vaccine provider based in China, focusing on delivering high-quality, affordable vaccines. Over the last sixteen years, it has created a robust system that adheres to international standards and has developed a diverse range of vaccines for more than ten infectious diseases. Dr. Yu Xuefeng expressed pride in representing Chinese biotechnology at the summit, emphasizing the company’s mission to advance public health initiatives. Looking ahead, CanSinoBIO plans to develop a competitive pipeline of new vaccines, including an inhaled tuberculosis vaccine and advanced polio vaccines.

Building Partnerships for Health

CanSinoBIO actively seeks partnerships worldwide to improve local vaccine production and address disparities. Since 2019, it has enhanced its global presence by expanding its team, boosting production, and collaborating with countries in the Middle East, Southeast Asia, and Latin America. The company’s quadrivalent meningococcal conjugate vaccine, Menhycia®, recently received a Halal Decree in Indonesia, making it a valuable option for the Muslim community. CanSinoBIO has also secured Halal certification for several of its vaccines, increasing accessibility for people in the MENA region.

With five advanced technology platforms, CanSinoBIO has developed numerous vaccines that protect against various illnesses such as meningitis, pneumonia, and COVID-19. Notably, its protein-based pneumococcal vaccine (PBPV) provides broad protection against many strains, while its non-infectious polio vaccine secured funding from the Bill & Melinda Gates Foundation, highlighting its potential in the fight against polio.